National Health Act 1953 Amendment special arrangements under subsection 100(1) Chemotherapy Pharmaceuticals Access Program (No. PB 114 of 2009) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 114 of 2009

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, DECLAN O’CONNOR-COX, Assistant Secretary, Access and Systems Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.

Dated 13 November 2009

DECLAN O’CONNOR-COX

Assistant Secretary

Access and Systems Branch

Department of Health and Ageing

Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program

1              Commencement

This instrument commences on 1 December 2009.

2              Amendment of PB 55 of 2009

Schedule 1 amends PB 55 of 2009.

Schedule 1   Amendments

[1]             Schedule 2, item dealing with Irinotecan in the forms I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL and
I.V. injection containing irinotecan hydrochloride trihydrate 100 mg
in 5 mL

in the column headed “Brand” insert in alphabetical order:

Irinotecan Alphapharm

[2]             Schedule 4, item dealing with Bleomycin (Blenoxane)

omit from the column headed “Price claimed by manufacturer”: 808.74

and substitute: 874.73

[3]             Schedule 4, item dealing with Folinic acid

(a)	omit from the column headed “Approved price”: 198.32
and substitute: 197.05
(b)	omit from the column headed “Price claimed by manufacturer”: 197.37
and substitute: 197.25

[4]             Schedule 4, item dealing with Ondansetron in the form I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL (Zofran)

(a)	omit from the column headed “Approved price”: 15.36
and substitute: 13.27
(b)	omit from the column headed “Price claimed by manufacturer”: 15.92
and substitute: 13.83

[5]             Schedule 4, item dealing with Ondansetron in the form I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL (Zofran)

(a)	omit from the column headed “Approved price”: 24.40
and substitute: 21.08
(b)	omit from the column headed “Price claimed by manufacturer”: 24.95
and substitute: 21.62